Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: a 9-month, open-label extension study.

[1]  L. Hill,et al.  Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. , 2009, The Journal of urology.

[2]  C. Roehrborn,et al.  α1‐Adrenoceptor subtypes and lower urinary tract symptoms , 2008, International journal of urology : official journal of the Japanese Urological Association.

[3]  M. Sasamata,et al.  In vivo study on the effects of alpha1-adrenoceptor antagonists on intraurethral pressure in the prostatic urethra and intraluminal pressure in the vas deferens in male dogs. , 2008, European journal of pharmacology.

[4]  M. C. Michel.  α1‐Adrenoceptors and ejaculatory function , 2007 .

[5]  S. Madersbacher,et al.  The long-term outcome of medical therapy for BPH. , 2007, European urology.

[6]  B. Djavan,et al.  Analysis of the functional role of ADAMTS enzymes in prostate cancer , 2005 .

[7]  C. Chapple.  A Comparison of Varying alpha-Blockers and Other Pharmacotherapy Options for Lower Urinary Tract Symptoms. , 2005, Reviews in urology.

[8]  H. Lepor.  Pathophysiology of lower urinary tract symptoms in the aging male population. , 2005, Reviews in urology.

[9]  C. Roehrborn,et al.  Safety and efficacy of alfuzosin 10 mg once‐daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double‐blind, placebo‐controlled studies , 2003 .

[10]  C. Chapple,et al.  Tamsulosin: an overview , 2002, World Journal of Urology.

[11]  H. Noto,et al.  Effect of KMD‐3213, an α1A‐adrenoceptor antagonist, on the prostatic urethral pressure and blood pressure in male decerebrate dogs , 2001, International journal of urology : official journal of the Japanese Urological Association.

[12]  H. Lepor,et al.  Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia. , 2001, Urology.

[13]  S. Yamada,et al.  In Vivo Demonstration of α1A-Adrenoceptor Subtype Selectivity of KMD-3213 in Rat Tissues , 2001 .

[14]  T. Taniguchi,et al.  TISSUE SELECTIVITY OF KMD-3213, AN α1-ADRENOCEPTOR ANTAGONIST, IN HUMAN PROSTATE AND VASCULATURE , 2000 .

[15]  H. Lepor.  Long-Term Evaluation of Tamsulosin in Benign Prostatic Hyperplasia: Placebo-Controlled, Double-Blind Extension of Phase III Trial , 1998 .

[16]  H. Lepor.  Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. , 1998, Urology.

[17]  K. Iizuka,et al.  Effect of KMD-3213, an alpha 1a-adrenoceptor-selective antagonist, on the contractions of rabbit prostate and rabbit and rat aorta. , 1996, European journal of pharmacology.

[18]  M. Barry,et al.  Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? , 1995, The Journal of urology.

[19]  G. Tsujimoto,et al.  KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues. , 1995, Molecular pharmacology.

[20]  T. Branchek,et al.  The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. , 1994, Molecular pharmacology.